Andy Chen

Q: What is Andy Chen's success rate?

Andy Chen currently has a success rate of 91.42372358784137.

Q: What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of 30.06938510003569.

Wolfe Research | Healthcare

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector. Ranked #834 out of 4771 analysts, they have issued 18 stock ratings with a success rate of 91.42% and an average return of 30.07%.

With 18 ratings to date, Andy Chen is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 91.42% and an average return of 30.07%, highlighting promising potential as their track record develops further.

#834

Out of 4771

Total Ratings

+91.42%

Success Rate

+30.07%

Average Return

Recent Ratings Analysis

MDGL

Buy

Aug 04, 2026

Target

$605.00

Current

$533.12

Performance

5.04%

Andy Chen rated MDGL as Outperform on Aug 04, 2026, setting a price target of 605. The call has proven timely, with shares rising 5.04% toward the price target of 605.

NTLA

Sell

Jul 16, 2026

Target

$9.00

Current

$11.93

Performance

0.59%

On Jul 16, 2026, NTLA was given a Underperform rating by Andy Chen, with a target price of 9. The stock traded sideways with only a 0.59% move, leaving the Sell case unresolved.

SRPT

Buy

Jul 09, 2026

Target

$27.00

Current

$20.52

Performance

0.00%

SRPT received a Outperform rating from Andy Chen on Jul 09, 2026, aiming for 27. Price action was muted, as shares hovered around 20.52 despite the bullish outlook.

DNTH

Buy

Apr 09, 2026

Target

$98.00

Current

$103.28

Performance

12.68%

On Apr 09, 2026, Andy Chen published a Outperform outlook on DNTH, with a target of 98. Shares gained 12.68%, underscoring the accuracy of the bullish outlook toward 98.

AVTX

Buy

Apr 09, 2026

Target

$48.00

Current

$17.18

Performance

20.90%

Andy Chen on Apr 09, 2026 assigned AVTX a Outperform rating, with a price target of 48. The Buy call aligned well with market performance, producing a gain of 20.90%.

PHVS

Buy

Apr 09, 2026

Target

$42.00

Current

$37.51

Performance

38.57%

On Apr 09, 2026, Andy Chen reaffirmed PHVS with a Outperform rating, targeting 42. The recommendation was supported by strong follow-through as the stock rose from 37.51 to 37.51.

PALI

Buy

Apr 09, 2026

Target

$7.00

Current

$2.01

Performance

1.52%

PALI was rated Outperform by Andy Chen on Apr 09, 2026, with a price objective of 7. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

MLTX

Buy

Mar 23, 2026

Target

$24.00

Current

$13.18

Performance

-21.87%

On Mar 23, 2026, Andy Chen initiated coverage on MLTX with a Outperform rating and target of 24. The Buy call has yet to be validated as shares remain 10.82 away from the target.

VERA

Buy

Mar 11, 2026

Target

$88.00

Current

$33.60

Performance

-20.08%

Andy Chen issued a Outperform recommendation for VERA on Mar 11, 2026, price target set at 88. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

APGE

Hold

Jan 07, 2026

Target

—

Current

$135.07

Performance

71.08%

On Jan 07, 2026, APGE was evaluated by Andy Chen, who gave a Peer Perform rating and target of null. Investors who stayed in despite the Hold saw upside of 71.08%.

IMVT

Buy

Jan 06, 2026

Target

$50.00

Current

$38.10

Performance

47.10%

Andy Chen rated IMVT as Outperform on Jan 06, 2026, setting a price target of 50. The call has proven timely, with shares rising 47.10% toward the price target of 50.

KYMR

Hold

Jan 06, 2026

Target

—

Current

$117.00

Performance

59.27%

On Jan 06, 2026, KYMR was given a Peer Perform rating by Andy Chen, with a target price of null. The stock rallied from 117 to 117 after the Hold rating, surprising to the upside.

VRTX

Buy

Jan 06, 2026

Target

$548.00

Current

$514.56

Performance

9.86%

VRTX received a Outperform rating from Andy Chen on Jan 06, 2026, aiming for 548. Momentum has favored the Buy call, with shares climbing from 514.56 to 514.56, rewarding those who trusted the recommendation.

ARGX

Hold

Nov 24, 2025

Target

—

Current

$984.04

Performance

8.53%

On Nov 24, 2025, Andy Chen published a Peer Perform outlook on ARGX, with a target of null. The Hold call missed some of the bullish momentum as shares advanced toward null.

APLS

Hold

Nov 06, 2025

Target

—

Current

$41.03

Performance

108.17%

Andy Chen on Nov 06, 2025 assigned APLS a Peer Perform rating, with a price target of null. Shares outperformed expectations, climbing 108.17% despite the neutral view.

AKRO

Hold

Oct 10, 2025

Target

—

Current

$54.65

Performance

1.43%

On Oct 10, 2025, Andy Chen reaffirmed AKRO with a Peer Perform rating, targeting null. The neutral call matched muted market action of 1.43%.

ETNB

Hold

Sep 19, 2025

Target

—

Current

$14.84

Performance

-0.20%

ETNB was rated Peer Perform by Andy Chen on Sep 19, 2025, with a price objective of null. Flat performance suggests the Hold view was reasonable.

ALNY

Hold

Aug 04, 2025

Target

—

Current

$247.51

Performance

-41.01%

On Aug 04, 2025, Andy Chen initiated coverage on ALNY with a Peer Perform rating and target of null. The rating matched the stock’s inability to hold above 247.51.

VRNA

Buy

Jul 01, 2025

Target

$170.00

Current

$106.91

Performance

18.16%

Andy Chen issued a Outperform recommendation for VRNA on Jul 01, 2025, price target set at 170. Investors following the Buy call captured upside momentum, with shares now at 106.91.

RNA

Buy

Jun 17, 2025

Target

$55.00

Current

$10.35

Performance

-64.75%

On Jun 17, 2025, RNA was evaluated by Andy Chen, who gave a Outperform rating and target of 55. Investors saw limited payoff as shares fell short of the 55 target.

BBIO

Buy

Jun 17, 2025

Target

$49.00

Current

$72.50

Performance

80.93%

Andy Chen rated BBIO as Outperform on Jun 17, 2025, setting a price target of 49. The call has proven timely, with shares rising 80.93% toward the price target of 49.

ZBIO

Buy

Feb 04, 2025

Target

$19.00

Current

$31.10

Performance

306.01%

On Feb 04, 2025, ZBIO was given a Outperform rating by Andy Chen, with a target price of 19. The stock rallied 306.01% after the rating, narrowing the gap to the target of 19 and validating the bullish stance.

ANAB

Buy

Feb 04, 2025

Target

—

Current

$55.16

Performance

234.10%

ANAB received a Outperform rating from Andy Chen on Feb 04, 2025, aiming for null. Momentum has favored the Buy call, with shares climbing from 55.16 to 55.16, rewarding those who trusted the recommendation.

CRNX

Hold

Feb 04, 2025

Target

—

Current

$84.95

Performance

110.27%

On Feb 04, 2025, Andy Chen published a Peer Perform outlook on CRNX, with a target of null. The Hold call missed some of the bullish momentum as shares advanced toward null.

ORKA

Buy

Feb 04, 2025

Target

$20.00

Current

$91.65

Performance

544.97%

Andy Chen on Feb 04, 2025 assigned ORKA a Outperform rating, with a price target of 20. The Buy call aligned well with market performance, producing a gain of 544.97%.

INCY

Buy

Oct 01, 2024

Target

—

Current

$123.28

Performance

81.13%

On Oct 01, 2024, Andy Chen reaffirmed INCY with a Outperform rating, targeting null. The recommendation was supported by strong follow-through as the stock rose from 123.28 to 123.28.

CLDX

Hold

Sep 27, 2024

Target

—

Current

$38.10

Performance

14.76%

CLDX was rated Peer Perform by Andy Chen on Sep 27, 2024, with a price objective of null. Despite caution, upside momentum rewarded risk-takers with gains to 38.1.

VRDN

Buy

Jun 11, 2024

Target

—

Current

$22.29

Performance

65.60%

On Jun 11, 2024, Andy Chen initiated coverage on VRDN with a Outperform rating and target of null. The stock’s climb of 65.60% since the call highlights the foresight in the rating.

RAPT

Hold

May 14, 2024

Target

—

Current

$58.01

Performance

81.27%

Andy Chen issued a Peer Perform recommendation for RAPT on May 14, 2024, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

Frequency Asked Questions

Who is Andy Chen?

Andy Chen is an analyst from Wolfe Research specializing in the Healthcare sector.

What is Andy Chen's success rate?

Andy Chen currently has a success rate of +91.42%.

How many ratings has Andy Chen issued?

Andy Chen has issued 18 stock ratings so far.

What is the average return of Andy Chen's calls?

Their stock ratings have generated an average return of +30.07%.

What is Andy Chen's ranking?

Andy Chen is ranked #834 out of 4771 analysts.

What types of ratings does Andy Chen give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andy Chen?

You can follow Andy Chen by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andy Chen?

Their latest rating was a Buy on MDGL issued on 2026-08-04.